share_log

Reported Sunday, Aadi Bioscience Presented New Subgroup Analysis Of Patients With Advanced Malignant PEComa Of Gynecologic Origin Treated With Nab-Sirolimus At Society Of Gynecologic Oncology

Moomoo 24/7 ·  Mar 18 02:24
  • Subgroup experienced efficacy and safety consistent with overall study population
  • Advanced malignant PEComa tumors of gynecologic origin accounted for more than half of the evaluable patients enrolled in AMPECT
  • Additional data presented highlight nab-sirolimus as potential approach for mTOR-driven gynecologic cancers
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment